Cancer immunotherapy has revolutionized oncology through dramatically increased survival rates, even in late-stage disease. Some biomarkers are already covered in what has become routine testing in many laboratories, affording pathologists an opportunity to play a central role in developing and implementing these biomarkers in ways to improve patient care, explains Eric Walk, MD, FCAP, Chief Medical & Scientific Officer and Senior VP of Medical & Scientific Affairs with Roche Diagnostics, in this CAPcast.

Dr. Walk recently wrote an article on this topic, which is posted on CAP.org under the Precision Medicine Resource Center: https://capatholo.gy/345u6dd.